ULTOMIRIS (ravulizumab)

OFFICE ADMINISTRATION

Indications for Prior Authorization:
  • Indicated in adults for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
The following criteria must be met for coverage:
  • Patient is of 18 years of age or older, AND
  • Patient has a diagnosis of PNH as confirmed by peripheral blood flow cytometry results showing the absence or deficiency of GPI-anchored proteins on at least 2 cell lineages, AND
  • Prescribed by or in consultation with a hematologist, AND
  • Patient does not have unresolved Neisseria Meningitidis infection.
Dosing:
  • Loading dose and maintenance doses are all administrated by intravenous infusion
  • ≥ 40 kg to < 60 kg:
    • Loading Dose: 2,400 mg
    • Maintenance Dose: 3,000 mg once every 8 weeks (starting 2 weeks after loading dose)
  • ≥ 60 kg to < 100 kg :
    • Loading Dose: 2,700 mg
    • Maintenance Dose: 3,300 mg once every 8 weeks (starting 2 weeks after loading dose)
  • ≥ 100 kg:
    • Loading Dose: 3,000 mg
    • Maintenance Dose: 3,600 mg once every 8 weeks (starting 2 weeks after loading dose)
Approval:
  • Initial: 6 months
  • Renewal: 1 year if the patient continues to derive benefit as confirmed by chart note documentation.

Last review date: May 22, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone